NHS access to the combination monoclonal antibody casirivimab plus imdevimab (marketed as Ronapreve®) has been extended in patients aged 12 and above and should now be considered at a total dose of 2.4g in COVID positive antibody seronegative patients who have been hospitalised specifically to manage the symptoms of COVID infection. A dose of 1.2g in patients who are admitted to hospital for another (non COVID-related) indication but nonetheless test positive during their hospital stay and are either at high risk of disease progression or COVID infection is considered to be likely to destabilise their existing medical condition or compromise recovery from their hospital procedure.
Further details of the recommendations can be found in the COVID-19 Therapeutic Alert
Want the latest pharmacy news and updates straight to your inbox?
Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.
Sign Up
Become an RPS Member today and save up to £26 by choosing annual Direct DebitOR spread the cost by switching to monthly payments.
RPS membership is better value than ever in 2024 - join today!
BECOME A MEMBER TODAY